Clinical Trial Update: Venetoclax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With Newly Diagnosed NPM1 Mutated AML [Phase 2]

View source ↗

Summary

This update describes a Phase 2 trial comparing venetoclax plus azacitidine against intensive chemotherapy in fit patients with newly diagnosed acute myeloid le…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Acute Myeloid Leukemia with Npm1 Mutation

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Venetoclax (venetoclax)

Snippet

Sponsor: Technische Universität Dresden | Conditions: Acute Myeloid Leukemia | Phase 2 | Status: RECRUITING